NASDAQ:ARTL • US04301G6070
Past quarterly earnings results for ARTELO BIOSCIENCES INC (ARTL), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Actual vs estimated values, surprises, q2q growth and acceleration numbers for recent quarters.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | -0.04 | -1.60 | 97.50% | 99.43% | - | - | ||
| Q3 2025 | -3.97 | -0.84 | -374.65% | -89.05% | - | - | ||
| Q2 2025 | -5.61 | -4.27 | -31.26% | -24.67% | - | - | ||
| Q1 2025 | -4.32 | -0.80 | -442.99% | 7.69% | - | - | ||
| Q4 2024 | -7.02 | -2.67 | -162.68% | -12.50% | - | - | ||
| Q3 2024 | -2.10 | -2.84 | 25.94% | 57.83% | - | - | ||
| Q2 2024 | -4.50 | -5.18 | 13.15% | -33.93% | - | - | ||
| Q1 2024 | -4.68 | -6.46 | 27.52% | -2.63% | - | - | ||
| Q4 2023 | -6.24 | -3.41 | -83.16% | 11.86% | - | - | ||
| Q3 2023 | -4.98 | -3.96 | -25.83% | -1.22% | - | - | ||
| Q2 2023 | -3.36 | -4.99 | 32.64% | 37.78% | - | - | ||
| Q1 2023 | -4.56 | -5.69 | 19.88% | -1.33% | - | - | ||
| Q4 2022 | -7.08 | -4.47 | -58.47% | -10,014.29% | - | - | ||
| Q3 2022 | -4.92 | -5.59 | 11.98% | -9,740.00% | - | - | ||
| Q2 2022 | -5.40 | -5.20 | -3.80% | -17,900.00% | - | - | ||
| Q1 2022 | -4.50 | -7.80 | 42.33% | -3,114.29% | - | - | ||
| Q4 2021 | -0.07 | -0.06 | -24.78% | 65.00% | - | - | ||
| Q3 2021 | -0.05 | -0.10 | 49.29% | 81.48% | - | - | ||
| Q2 2021 | -0.03 | -0.09 | 67.32% | 92.50% | - | - | ||
| Q1 2021 | -0.14 | -0.12 | -19.35% | 65.00% | - | - | ||
| Q4 2020 | -0.20 | -0.10 | -96.08% | - | - | - | ||
| Q3 2020 | -0.27 | -0.37 | 26.47% | - | - | - | ||
| Q2 2020 | -0.40 | -0.41 | 1.96% | - | - | - | ||
| Q1 2020 | -0.40 | -0.54 | 26.01% | - | - | - |
Notes
ARTELO BIOSCIENCES INC (ARTL) last reported earnings on 2/24/2026.
ARTELO BIOSCIENCES INC (ARTL) beat EPS estimates and missed revenue estimates in the most recent quarter.
In the last 4 quarters, ARTELO BIOSCIENCES INC (ARTL) has beaten EPS estimates in 0 out of 4 releases.